Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (PEGINVERA)
This study is ongoing, but not recruiting participants.
Study NCT01193699   Information provided by AOP Orphan Pharmaceuticals AG

First Received on September 1, 2010.   Last Updated on January 22, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Polycythemia Vera
Additional conditions recognized in this trial
Polycythemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Myeloproliferative Disorders
Interventions listed in this trial
PEG-P-INF alpha-2b (P1101)
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon Alfa-2b
Interferon-alpha
Interferons
Peginterferon alfa-2b
Reaferon
More general drug interventions related to this trial
Adjuvants, Immunologic
Alcohol Deterrents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
AOP Orphan Pharmaceuticals AG


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services